Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Addressing Gaps in Chronic Prurigo Management: Evidence-Based Diagnostic and Treatment Guidelines from a Delphi Consensus Panel

  • By

  • Pedro Mendes-Bastos

  • Inês Lobo

  • Gilberto Pires da Rosa

  • Rita Pimenta

  • Margarida Gonçalo

  • August 11, 2026

Share

  • 1

    The article corrects a statement regarding dupilumab reimbursement in Portugal, confirming it was reimbursed in January 2025.

  • 2

    An error in the dosage for lebrikizumab was corrected from '125 mg every 4 weeks' to '250 mg every 2 weeks'.

  • 3

    Tralokinumab's dosage was also corrected to '300 mg every 2 weeks' in the treatment section.

  • 4

    The corrections were made to ensure accurate information regarding chronic prurigo management.

  • 5

    The article has been officially amended to reflect these corrections.

Original Source(s)

Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel

  • by Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta, Margarida Gonçalo

  • August 11, 2026

Related Content

Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension

The “two flowers therapy”: clinical efficacy and mechanisms of a total glucosides of paeony -colchicine dual-drugs for Behçet’s disease derived from Chinese physicians’ medication experience

A hybrid deep learning and cellular automata framework with fractional derivatives for skin type and skin disease classification